ESR1 and breast carcinoma: Therefore, we tested riluzole's activity in combination with the SERD fulvestrant or SERM tamoxifen (4-hydroxytamoxifen) in ILC- and IDC-derived ER+ breast cancer cell lines and the ER− nontransformed breast epithelial cell line MCF10A as a negative control.